China’s Strategic Advance in the Global Biosimilars Market: Implications for Biopharma Competition and Innovation
China has transitioned from a generics and API producer to a formidable global competitor in biosimilars, securing international regulatory approvals and forming strategic partnerships that enhance its presence in key markets. This evolution signals a broader shift in China’s pharmaceutical industry towards innovation, quality, and global integration.